Table 1: FURI Outcomes by Fungal Disease

| Fungal Disease Type | Complete or Partial Response | Stable Response | Progression of Disease | Indeterminate Partials |
|---------------------|------------------------------|-----------------|------------------------|-----------------------|
| N                  | N (%) | N (%) | N (%) | N (%) |
| Invasive Candidiasis| Candidemia       | 11              | 8 (72.7%) | 1 (9.0%) | 1 (9.0%) | 1 (9.0%) |
|                    | Intra-abdominal infections | 14              | 7 (50%)  | 3 (21.4%) | 2 (14.2%) | 1 (7.1%)  |
|                    | Benignancy        | 8               | 5 (62.5%) | 2 (25%)   | 1 (12.5%)  |
|                    | Urinary tract infection | 2               | 1 (100%) |
|                    | Subcutaneous wound infection | 2              | 1 (100%) |
|                    | Mediastinitis     | 1               | 1 (100%)  |
|                    | Empyema           | 1               | 1 (100%)  |
|                    | Endocarditis      | 1               | 1 (100%)  |
| Muco-cutaneous Candidiasis | Oropharyngeal candidiasis | 14              | 9 (64.3%) | 3 (21.4%) | 2 (14.3%) |
|                    | Esophageal candidiasis | 10              | 6 (60%)   | 4 (40%)   |
|                    | Vulvovaginal candidiasis | 7               | 5 (71.4%) | 1 (14.3%) |
|                    | Chronic mucocutaneous candidiasis-skin | 1 | 1 (100%) |
| Invasive Aspergillosis | Pulmonary         | 3               | 2 (66.7%) | 1 (33.3%) |

1 Death, not related to fungal disease

**Methods.** FURI patients were eligible for enrollment if they have proven or probable, severe muco-cutaneous candidiasis, invasive candidiasis or invasive aspergillosis, other fungal diseases and evidence of failure to, intolerance to, or toxicity related to a currently approved standard-of-care antifungal treatment or can not receive approved oral antifungal options (e.g., susceptibility of the organism) and a continued IV antifungal therapy is clinically undesirable or unfeasible.

**Results.** An independent Data Review Committee (DRC) provided an assessment of treatment response for 74 patients enrolled in the FURI study from 22 centers in US, UK and EU treated with irexafungerp for muco-cutaneous or invasive fungal infections from 2016-2020. A total of 39 (52.7%) patients had invasive candidiasis, 32 (43.2%) had muco-cutaneous candidiasis and 3 (4.5%) patients had invasive aspergillosis. The percent of patients who were determined to have a complete response (CR), partial response (PR), clinical improvement (CI) was 63.5%, stable disease (SD) was 23.0%, patients with progression of disease 6.8% and 4 patients were indeterminate. Additionally, there was 1 death in the FURI study that was not related to fungal disease.

**Conclusion.** Analysis of 74 patients from the FURI study indicates that oral irexafungerp provides a favorable therapeutic response in patients with challenging fungal disease and limited treatment options.

**Disclosures.** Peter G. Pappas, MD; Astellas (Research Grant or Support); Cidara (Research Grant or Support); F2G (Consultant); Matinas (Consultant, Scientific Research Study Investigator); Mypha Pharma (Research Grant or Support); Synexis (Research Grant or Support); Oliver Cornely, Prof., Actelion (Consultant, Grant/Research Support); A- Jazera Pharmaceuticals (Consultant); Allcera Therapeutics (Consultant) Amplexy (Consultant, Grant/Research Support); Astellas (Consultant, Grant/Research Support); Basilea (Consultant, Grant/Research Support); Biocoon (Consultant); Biosys (Consultant); Cidara (Consultant, Grant/Research Support); CoRe Consulting (Consultant); Da Volterra (Consultant, Grant/Research Support); DFG (German Research Foundation) (Consultant, Grant/Research Support); Entasis (Consultant); F2G (Consultant, Grant/Research Support); German Federal Ministry of Research and Education (Grant/Research Support); Gilead (Consultant, Grant/Research Support); Grupo Biotoscana (Consultant); Immunic (Consultant, Grant/Research Support); IQLVIA (Consultant); Janssen (Grant/Research Support); Matinas (Consultant, MedPace (Consultant, Grant/Research Support); Mypharma (Consultant, Grant/Research Support); Scynexis (Consultant, Grant/Research Support); Seres (Consultant); Shinogi (Consultant, Wiley (Blackwell) (Other Financial or Material Support); Philipp Koehler, MD, Ambu GmbH (Consultant, Speaker’s Bureau); Astellas Pharma (Speaker’s Bureau); European Confederation of Medical Mycology (Speaker’s Bureau); German Federal Ministry of Research and Education (Grant/Research Support); Gilead (Consultant, Speaker’s Bureau); MSD (Speaker’s Bureau); Noxxon N.V. (Consultant); Pfizer (Consultant, Speaker’s Bureau); State of North Rhine-Westphalia, Germany (Grant/Research Support); Todd P. McCarty, MD, Cidara (Grant/Research Support); GenMark (Grant/Research Support); Other Financial or Material Support, Honoraria for Research Presentation); T2 Biosystems (Consultant); Barbara D. Alexander, MD, MHS, SCYNEXIS, Inc. (Consultant); Rachel Miller, MD, SCYNEXIS, Inc. (Scientific Research Study Investigator); Caryl Morse, MD, Chimerix (Scientific Research Study Investigator); Covis Pharma (Scientific Research Study Investigator); Gilead Sciences Inc. (Scientific Research Study Investigator); Ridgeback Biotherapeutics (Scientific Research Study Investigator); Roche (Scientific Research Study Investigator); Scynexis (Grant/Research Support, Scientific Research Study Investigator); Viracor (Consultant); Jürgen Pratten, Dr., AbbVie Inc. (Shareholder); Gilead (Grant/Research Support, Speaker’s Bureau); Pfizer (Scientific Research Study Investigator, Speaker’s Bureau); Scynexis (Consultant, Scientific Research Study Investigator); Stryker (Consultant); Andrej Spec, MD, MSCI, Mayne Pharma (Grant/Research Support); Riina Rauteama-Richardson, DDS, PhD, FRCPath, SCYNEXIS, Inc. (Scientific Research Study Investigator); Thomas J. Walsh, MD, PhD (hon), Scynexis (Consultant, Grant/Research Support); Shionogi (Consultant, Scientific Research Study Investigator); Marisa Miceli, MD, SCYNEXIS, Inc. (Advisor or Review Panel member); Martin Hoenigl, MD, Astellas (Grant/Research Support); Gilead (Grant/Research Support); Pfizer (Grant/Research Support); Martin Hoenigl, MD, Astellas (Individual(s) Involved: Self); Grant/Research Support; F2G (Individual(s) Involved: Self); Grant/Research Support; Gilead (Individual(s) Involved: Self); Grant/Research Support; Pfizer (Individual(s) Involved: Self); Grant/Research Support; Scynexis (Individual(s) Involved: Self); Grant/Research Support; Thomas F. Patterson, MD, SCYNEXIS, Inc. (Advisor or Review Panel member); Nkechi Azie, MD, SCYNEXIS, Inc. (Employee, Shareholder); David A. Angulo, MD, SCYNEXIS, Inc. (Employee, Shareholder)

124. Establishment of a Post-Influenza Aspergillosis Model in Corticosteroid-Immunosuppressed Mice

Sebastian Wurster, MD; Izrael Pantaleón García, MD; Nathaniel D. Albert; Scott Evans, MD; Dimitrios P. Kontoyiannis, MD; The University of Texas MD Anderson Cancer Center, Houston, TX

**Session:** O-25. New Findings in Medical Mycology

**Background.** Post-influenza aspergillosis (PIA) is a feared complication in patients with severe influenza, especially those receiving corticosteroids. However, validated murine models of PIA in a background of corticosteroid immunosuppression are lacking, compounding efforts to better characterize the immunopathology and treatment of this emerging entity.

**Methods.** 8-week-old female BALB/c mice were infected with ~5% of the lethal dose of a mouse-adapted influenza A/Hong Kong/1968 (H3N2) strain (flu), delivered by aerosolization, versus control (aerosolized saline). Mice then received two intraperitoneal injections of 10 mg cortisone acetate (CA) or mock injections on days 5 and 8 after flu injection. On day 9, mice were intranasally challenged with 50,000 A. fumigatus AF-293 conidia or mock-infected with...
Flu infection alone caused modest early morbidity, followed by full recovery of the mice until day 16. Treatment with CA after flu infection led to 12% mortality and increased morbidity that persisted until day 16 (median MSS = 0.8). Similarly, mice infected with AF after CA treatment had 12% mortality and a median MSS of 0.7. Combination of all 3 challenges (flu, CA, and AF) led to 40% mortality and severe morbidity in surviving mice (median MSS = 2.7). Likewise, prior flu infection of CA-treated, AF-infected mice increased the pulmonary fungal burden from 27k to 80k median conidial equivalents. In contrast, mice not receiving CA treatment showed consistently low morbidity (median day-16 MSS = 0.5) and minimal fungal burden after AF challenge, regardless of prior flu infection.

**Conclusion.** We have established a model of PIA in CA-immunosuppressed mice that underscores the detrimental effect of corticosteroid therapy on the outcomes of PIA. In the future, we will employ this model to study the impact of various pharmacological interventions on the natural history of PIA in the background of corticosteroid immunosuppression.

**Disclosures.** Dimitrios P. Kontoyiannis, MD; Astellas (Consultant); Gidara Therapeutics (Advisor or Review Panel member); Gilead Sciences (Consultant, Grant/Research Support, Other Financial or Material Support, Honoraria)

125. Dynamic PET facilitated Pharmacokinetic Modeling and High-dose Rifampin Regimens for *Staphylococcus aureus* Orthopedic Implant Associated Infections: Bench to Bedside

Oren Gordon, MD PhD; Donald Lee, n/a; Brooke Langevin, n/a; Alvina A. Ordonez, MD; Dustin Dikeman, n/a; Babar Shafiq, MD; John Thompson, MD; Kelly Flahahan, n/a; Martin Lodge, PhD; Steven Rowe, MD PhD; Robert Dannals, PhD; Camilo Ruiz-Bedoya, MD; Timothy D. Read, PhD; Nathan Archer, PhD; Lloyd Miller, MD PhD; Jorgaro Gobburu, PhD; Sanjay K. Jain, MD; Sanjay K. Jain, MD; Johns Hopkins, Baltimore, Maryland; Johns Hopkins University School of Pharmacy, Baltimore, Maryland; Emory University Atlanta, Georgia

**Session:** O-26. New Insights into Microbial Pathogenesis

**Background.** Rifampin, has potent, dose-dependent sterilizing activity against Gram-positive bacteria with the area under the concentration-time curve (AUC) being the most predictive of bactericidal activity. Combination therapy with rifampin (10-15 mg/kg/day) is recommended to treat *S. aureus* orthopedic implant associated infections. Recently, high-dose rifampin (35 mg/kg/day) has been shown to be safe in humans and is being evaluated to shorten tuberculosis treatments.

**Methods.** Dynamic $^{11}$C-rifampin (chemically identical to rifampin) positron emission tomography (PET) was used to determine rifampin bone exposures (AUC) in mice and patients with *S. aureus* bone infection (Figure 1). PET data facilitated a pharmacokinetic model to predict rifampin concentration-time profiles in bone tissues, which were used to design studies in a mouse model of *S. aureus* orthopedic implant infection utilizing advanced imaging.

**Results.** $^{11}$C-Rifampin PET median bone to plasma AUC ratio was 0.14 (IQR 0.09 – 0.19) in patients with *S. aureus* bone infection (Figure 1). PET data facilitated a pharmacokinetic model to predict rifampin concentration-time profiles in bone tissues, which were used to design studies in a mouse model of *S. aureus* orthopedic implant infection utilizing advanced imaging.

(A) A validated mouse model of *S. aureus* orthopedic implant associated infection was used to determine bone concentrations following administration of escalating rifampin oral dosing (human equipotent dosing is indicated). m/z, mass/charge ratio. (B) Human patients and mice with *S. aureus* orthopedic infection were imaged using $^{11}$C-rifampin PET / CT. PET signal was quantified in infected and uninfected bone to generate time-activity curves (TACs) used to calculate area under the concentration time curve (AUC) over 45-90 minutes. These data were used to develop a pharmacokinetic model to predict rifampin exposures in bone. (C) Efficacy studies in mice compared vancomycin alone to vancomycin with either standard-dose or high-dose rifampin. (D) Readouts included weekly in vivo bioluminescence, bacterial load and broth cultures at completion of follow up and CT to evaluate adverse bone remodeling. (E) Bacterial isolates were evaluated for phenotypic resistance as well as subjected to whole genome sequencing. (F) Human studies were approved by the Johns Hopkins University Institutional Review Board Committee. Patients were prospectively recruited at the Johns Hopkins Hospital and $^{11}$C-rifampin PET was performed under the U.S. FDA Radioactive Drug Research Committee program guidelines for investigational drugs. Animal studies were approved by the Johns Hopkins Animal Care and Use Committee. Approvals from the Johns Hopkins Biosafety and Radiation Safety were also obtained for all studies.

**Results.** $^{11}$C-Rifampin PET median bone to plasma AUC ratio was 0.14 (IQR 0.09 – 0.19) in patients (Figure 2A-E), lower than previously reported using single time-point measures. Pharmacokinetic simulations and tissue measurements demonstrated that administration of high-dose rifampin leads to substantial increases in bone tissue concentrations (Figure 2F-G). Importantly, 4-weeks of high-dose rifampin administered in combination with vancomycin was non-inferior to the 6-weeks combination treatment with standard dose rifampin and vancomycin, recommended by the IDSA [risk difference: -6.7% (-20% – 6.9%) favoring high-dose rifampin] (Figure 3). Finally, high dose rifampin ameliorated antimicrobial resistance (0% vs 40%; P = 0.06), genetic alterations related to persistence (whole-genome bacterial sequencing) (Figure 4A-B) and mitigated adverse bone remodeling (high-resolution computed tomography) (Figure 4C-D).